Xiaoxu Wang

Dr. Xiaoxu Wang


Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 November 2018 in Oncology Letters
Verified
Journal Article
Open access
PDF file
JLJue Liu
Jue Liu
XZXiaobo Zhang
Xiaobo Zhang
YHYuliang Huang
Yuliang Huang
QZQunfeng Zhang
Qunfeng Zhang
JZJianbin Zhou
Jianbin Zhou
XWXiaoxu Wang
Xiaoxu Wang
Cisplatin is a first‑line chemotherapy drug that is commonly used in the treatment of epithelial ovarian cancer (EOC). However, insensitivity to cisplatin markedly influences the outcomes of chemotherapy. MicroRNAs (miRNAs/miRs) have been demonstrated to modulate drug resistance in a number of types of cancer. The aim of the present study was to investigate the key miRNAs involved in modulating drug resistance in ovarian cancer cells. miR‑200b and miR‑200c were identified to be frequently deregulated in ovarian cancer. Upregulation of miR‑200b and miR‑200c promoted EOC cell death in the presence of cisplatin. Upregulation of miR‑125b‑5p significantly decreased tumor growth in combination with cisplatin in a mouse model. Significantly, miR‑200b and miR‑200c reversed cisplatin resistance by targeting DNA methyltransferases (DNMTs) (directly targeting DNMT3A/DNMT3B and indirectly targeting DNMT1 via specificity protein 1). These results indicate that miR‑200b‑ and miR‑200c‑mediated regulation of DNMTs serves a crucial function in the cellular response to cisplatin. miR‑200b‑ and miR‑200c‑mediated downregulation of DNMTs may improve chemotherapeutic efficacy by increasing the sensitivity of cancer cells and thus may have an impact on ovarian cancer therapy.

19 September 2016 in Tumor Biology
Verified
Journal Article
Closed access
PDF file
ZLZheng-Xuan Liu
Zheng-Xuan Liu
LHLiang Hong
Liang Hong
SFSong-Qing Fang
Song-Qing Fang
GTGuang-Hua Tan
Guang-Hua Tan
PHPei-Guan Huang
Pei-Guan Huang
XWXiaoxu Wang
Xiaoxu Wang

8 November 2016 in Oncotarget
Verified
Journal Article
Open access
PDF file
JLJue Liu
Jue Liu
MZMing Zhu
Ming Zhu
XXXue Xia
Xue Xia
YHYuliang Huang
Yuliang Huang
QZQunfeng Zhang
Qunfeng Zhang
XWXiaoxu Wang
Xiaoxu Wang
Jumonji domain-containing protein 1A promotes cell growth and progression via transactivation of c-Myc expression and predicts a poor prognosis in cervical cancer Jumonji domain-containing protein 1A promotes cell growth and progression via transactivation of c-Myc expression and predicts a poor prognosis in cervical cancer

8 January 2021 in Experimental and Therapeutic Medicine
Verified
Journal Article
Open access
PDF file
DCDawei Cai
Dawei Cai
HYHuyong Yan
Huyong Yan
JLJun Liu
Jun Liu
SCSichun Chen
Sichun Chen
LJLonghai Jiang
Longhai Jiang
JQJian Qin
Jian Qin
Osteoarthritis (OA) is a common joint disorder characterized by progressive articular cartilage degeneration and destruction and results in gradual disability among middle‑aged and elderly patients. Our previous study demonstrated that depletion of nuclear factor erythroid 2‑related factor 2 (Nrf2) exacerbated cartilage erosion in an OA model and that activation of the Nrf2 pathway could counter this process. As a downstream target of Nrf2, heme oxygenase (HO) degrades heme to free iron, biliverdin and carbon monoxide (CO), which protects against oxidative stress. Ergosterol (ER), which is extracted from fungi, is a newly discovered Nrf2 activator and displayed efficacy against myocardial injury. The present study aimed to investigate the potential protective effects of ER against cartilage damage during OA. Primary mouse chondrocytes were treated with ER for in vitro assays. Furthermore, mice that underwent destabilization of the medial meniscus surgery were orally administered with ER. Western blotting suggested that ER increased protein expression of Nrf2 and HO‑1 in primary chondrocytes and articular cartilage from knee joints. Cartilage damage in knee joints was significantly reduced by ER treatment. Western blotting and PCR analysis confirmed that ER could also suppress the expression of MMP‑9 and MMP‑13 in vivo and in vitro. The present findings suggested that ER effectively alleviated cartilage degradation and that activation of the Nrf2‑heme oxygenase 1 pathway may play a role in ER‑mediated cartilage protection against OA.

9 December 2023 in Heliyon
Verified
Journal Article
Open access
CHChunrong He
Chunrong He
FLFangfang Lu
Fangfang Lu
YLYi Liu
Yi Liu
YLYuanhu Lei
Yuanhu Lei
XWXiaoxu Wang
Xiaoxu Wang
NTning tang
ning tang
With the burgeoning advancements in disease modeling, drug development, and precision medicine, organ-on-a-chip has risen to the forefront of biomedical research. Specifically in tumor research, this technology has exhibited exceptional potential in elucidating the dynamics of metastasis within the tumor microenvironment. Recognizing the significance of this field, our study aims to provide a comprehensive bibliometric analysis of global scientific contributions related to organ-on-a-chip. Publications pertaining to organ-on-a-chip from 2014 to 2023 were retrieved at the Web of Science Core Collection database. Rigorous analyses of 2305 articles were conducted using tools including VOSviewer, CiteSpace, and R-bibliometrix. Over the 10-year span, global publications exhibited a consistent uptrend, anticipating continued growth. The United States and China were identified as dominant contributors, characterized by strong collaborative networks and substantial research investments. Predominant institutions encompass Harvard University, MIT, and the Chinese Academy of Sciences. Leading figures in the domain, such as Dr. Donald Ingber and Dr. Yu Shrike Zhang, emerge as pivotal collaboration prospects. Lab on a Chip, Micromachines, and Frontiers in Bioengineering and Biotechnology were the principal publishing journals. Pertinent keywords encompassed Microfluidic, Microphysiological System, Tissue Engineering, Organoid, In Vitro, Drug Screening, Hydrogel, Tumor Microenvironment, and Bioprinting. Emerging research avenues were identified as "Tumor Microenvironment and Metastasis," "Application of organ-on-a-chip in drug discovery and testing" and "Advancements in personalized medicine applications". The organ-on-a-chip domain has demonstrated a transformative impact on understanding disease mechanisms and drug interactions, particularly within the tumor microenvironment. This bibliometric analysis underscores the ever-increasing importance of this field, guiding researchers and clinicians towards potential collaborative avenues and research directions.

9 July 2024 in Journal of Hospital Infection
Verified
Journal Article
Closed access
YLY. Lei
Y. Lei
YZY. Zeng
Y. Zeng
ZLZ. Li
Z. Li
ZXZ. Xiao
Z. Xiao
GTG. Tang
G. Tang
XWXiaoxu Wang
Xiaoxu Wang